Ibrutinib Effects on Graft-Versus-Host Disease in Mouse Models

Data from a study evaluating the Bruton's Tyrosine Kinase and IL-2 Inducible T-cell Kinase inhibitor ibrutinib for preventing chronic graft-versus-host disease (cGVHD). The research tested ibrutinib across four different mouse models, finding it significantly alleviated cGVHD and increased long-term survival. The dataset includes measurements of clinical scores, serum autoantibodies, costimulatory molecule activation, B-cell proliferation, and glomerulonephritis.

Use Cases

• Analyze the correlation between reduced clinical scores and decreased serum autoantibody levels in ibrutinib-treated mice.
• Model the relationship between B-cell proliferation data and the incidence of glomerulonephritis across different mouse models of cGVHD.
• Compare costimulatory molecule activation metrics between vehicle control and ibrutinib-treated groups to quantify drug efficacy.
• Assess long-term survival rates against clinical score trajectories for mice in the four different experimental models.

Strengths

• Data is derived from testing across four distinct mouse models of graft-versus-host disease, providing comparative evidence.
• Study measures multiple biological endpoints including clinical scores, survival, autoantibodies, and cellular proliferation.
• Dataset is published under a permissive CC0 1.0 public domain dedication license.

Limitations

• Data is derived from preclinical mouse models, limiting direct applicability to human clinical outcomes.
• Specific sample sizes, row counts, and file structures for the underlying data are not provided in the description.

Provenance

Source

Dryad digital repository, authored by Steven D. Schutt.

Collection Method

Experimental data from a study testing ibrutinib in mouse models of acute and chronic graft-versus-host disease.

Freshness

Last updated in June 2020.